ROYALTY PHARMA PLC (RPRX) — Hedge Fund Ownership Q1 2026
RPRX
- ROYALTY PHARMA PLC (RPRX) is held by 3 of 84 tracked hedge funds, with Dorsey Asset Management (9%) and Patient Capital Management (7%) holding the largest stakes, indicating limited hedge fund interest relative to peers.
- The biggest increases in RPRX holdings came from Patient Capital Management (+9%) and Dorsey Asset Management (+1%), highlighting conviction.
- The biggest decreases in RPRX holdings came from Torray Investment Partners (-13%), suggesting profit-taking or de-risking.
- Overall, hedge funds increased exposure to ROYALTY PHARMA PLC (RPRX) by +4% vs the prior quarter and +12% vs prior year.
| # | Fund | % of Portfolio † | Shares † | Shares vs Prior Quarter † | Shares vs Prior Year † | Aggregate Value † | Reported Price * | Option |
|---|---|---|---|---|---|---|---|---|
| 1 |
Dorsey Asset Management Pat Dorsey
|
8.70% | 2.3M | +0.76% | — | $109.2M | $47.97 | — |
| 2 |
Patient Capital Management Samantha McLemore
|
6.52% | 3.6M | +9.30% | +22.57% | $174.8M | $47.97 | — |
| 3 |
Torray Investment Partners Robert Torray
|
4.54% | 645K | -13.29% | -25.13% | $31.0M | $47.97 | — |
| 3 | Total | — | 6.6M | +3.60% | +11.85% | $315.0M | — | — |
* Reported price is not an actual purchase or sale price. It is the price as of the last portfolio date.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.